GSK first-quarter beats estimates on shingles vaccine surge
Updated : May 01, 2019 05:48 PM IST
The company said its quarterly earnings were hurt by continuing price pressure and other investments in promotional product support, particularly for new launches.
Adjusted operating profit was 30.1 pence per share in the quarter versus expectations of 26.1 pence per share.
Sales of Shingrix, the vaccine launched in 2017, were 357 million pounds in the first quarter, up 61.5 percent from a fourth quarter in which they also doubled.